Is the Run in Biotechnology Stocks Over?

By

Run in Biotechnology Stocks OverOne of the stock market’s strongest sectors over the last few years has been biotechnology stocks. It’s a very tough group in which to be a speculator, because you cannot predict discoveries or approvals. What you can do, though, is play the news flow while gauging sentiment in the stock market.

The NASDAQ Biotechnology Index has been on a tear for the last four years, and according to Reuters, the U.S. Food and Drug Administration (FDA) approved 39 new drugs and biological products last year. This compares to 30 in 2011 and 21 in 2010. It is the highest number, beating the previous high reached in 1996, when 35 new drugs were approved. (Source: Hirschler, B. and Humer, C., “FDA new drug approvals hit 16-year high in 2012,” Reuters, last accessed March 21, 2013.)

On the stock market, anything can happen with biotechnology stocks, and you can lose your shirt pretty quickly. Opko Health, Inc. (NYSE/OPK) is one of those biotechnology stocks that perfectly illustrate the challenges of trading in the group.

Opko is a biotechnology aggregator; it has its hand in a lot of developments. The company is run by Dr. Phillip Frost, who became a billionaire when he sold his last pharmaceutical company to a major drug manufacturer. Opko’s stock chart is featured below:

OPK Opko Health Inc stock market chart

Chart courtesy of www.StockCharts.com

For months and months, Frost was buying shares in Opko Health on the stock market (all open market, public and documented), but the price didn’t move. This went on and on until the company announced an expanded collaboration with Bristol Myers-Squibb Company (NYSE/BMY) for one of its diagnostic tests. Then, bam! Opko’s shares exploded on the stock market.

Biotechnology stocks are like this, but the tough part is that you have to be watching them all the time. (See “High Risk, High Reward—Two Great Companies for Traders.”) They can also move in the opposite direction with equal fervor.

The NASDAQ Biotechnology Index has continued momentum. The good thing about most biotechnology stocks is that they have little correlation to the broader stock market; they dance to their own tune, for sure.

Because there is so much money in pharmaceuticals, institutional participation within the sector is very strong. Among developing biotechnology stocks, virtually the only players are institutions (and billionaires).

A trader can piggyback on the news in biotechnology stocks, but you have to be prepared to quickly jump ship. The action in this group continues to have momentum, and FDA approvals should maintain a strong pace this year. The whole sector is, of course, 100% speculative.

Retire on one hot stock

Presenting Our Top Stock Pick for 2015!

It is one of the leading companies in its industry. With quarterly revenue of $800 million and growing this company is generating over $300 million every three months in free cash flow!

"A Golden Opportunity for Stock Market Investors" is yours FREE when you opt-in to get our daily e-letter Profit Confidential. With Profit Confidential you are receiving the opinions and commentaries of seasoned financial analysts and economists. We analyze the actions of the stock market, precious metals, interest rates, real estate, and other investments so we can tell you what we believe today's financial news will mean for you tomorrow!

Combined, we have over 100 years' experience in analyzing various investment markets. Our analysts include MBAs, BAs, B.Comms, P.Engs, MAs, LLBs...and most importantly, years of experience investing and managing our own money successfully!

To opt-in to our FREE e-letter Profit Confidential and to get your FREE report, "A Golden Opportunity for Stock Market Investors," enter your e-mail address in the box below. You can unsubscribe at any time.

We hate spam as much as you do. Check out our Privacy Policy.

About the Author | Browse Mitchell Clark's Articles

Mitchell Clark is a senior editor at Lombardi Financial, specializing in large- and micro-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, including Micro-Cap Reporter, Income for Life, Biotech Breakthrough Stock Report, and 100% Letter. Mitchell has been with Lombardi Financial for 17 years. He won the Jack Madden Prize in economic history and is a long-time student of equity markets. Prior to joining Lombardi, Mitchell was a stockbroker for a large investment bank. In the... Read Full Bio »

Related Articles

Video: Here is why you should be Bullish on Gold | By: Michael Lombardi

Poll

Would you vote for Donald Trump if he was the Republican Nominee?

View Results

Loading ... Loading ...
Profit Confidential
×
54.196.238.210
From: Michael Lombardi, MBA
Subject: Gold: The Stock Contrarian Investors’ Best Play of the Decade

Read this message